AXERION THERAPEUTICS
Axerion Therapeutics, Inc. is a private Connecticut-based biotechnology company focused on developing innovative therapeutics for neurological diseases and injuries with significant unmet medical need, including Alzheimer’s disease and spinal cord injury. Axerion was established in New Haven to develop and commercialize intellectual property licensed from Dr. Stephen Strittmatter’s laboratory at Yale University. Axerion’s proprietary technology platforms include blockers of ß-amyloid (Aß) oligomers binding to Prion Proteins (PrP) on the cell surface of neurons as a novel therapeutic target for Alzheimer’s disease and Nogo Receptor decoy protein for recovery of neurological function in spinal cord injury and other neurological diseases.
AXERION THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2009-01-01
Address:
New Haven, Connecticut, United States
Country:
United States
Website Url:
http://www.axeriontherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
2032032389
Email Addresses:
[email protected]
Total Funding:
1.15 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API WordPress Apache Wordpress Plugins Sitelinks Search Box Yoast WordPress SEO Plugin ReCAPTCHA
Similar Organizations
Alethia BioTherapeutics
Alethia BioTherapeutics is a biotechnology company developing monoclonal antibody-based therapeutics for cancer-associated diseases.
Ceptaris Therapeutics
Ceptaris Therapeutics is a pharmaceutical company developing therapeutics for symptoms of early-stage mycosis fungoides.
Current Advisors List
Founder
Investors List
Connecticut Innovations
Connecticut Innovations investment in Venture Round - Axerion Therapeutics
Connecticut Innovations
Connecticut Innovations investment in Seed Round - Axerion Therapeutics
Official Site Inspections
http://www.axeriontherapeutics.com
Unable to get host informations!!!
